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Abstract There are over 385,000 cases of atrial fibrillation
(AF) in the Netherlands, with over 45,000 new cases each
year. Among other things, AF patients are at high risk of
stroke. Patients are often prescribed oral anticoagulation,
such as vitamin K antagonists (VKA), to mitigate these
risks. A recently introduced class of oral anticoagulants,
non-vitamin K antagonists (NOAC), is quickly gaining cur-
rency in global clinical practice. This study provides insight
into the changes these new drugs will bring about in Dutch
clinical practice.
GARFIELD-AF is a large-scale observational AF patient
registry initiated in 2009 to track the evolution of global
anticoagulation practice, and to study the impact of NOAC
therapy in AF in particular. The registry includes a wide
array of baseline characteristics and has a particular focus
on: (1) bleeding and thromboembolic events; (2) interna-
tional normalised ratio fluctuations; and (3) therapy com-
pliance and persistence patterns. The results in this paper
provide the baseline characteristics of the first cohorts of
Dutch participants in this registry and discuss some of the
consequences of the changes in anticoagulation practice.
Although VKA therapy remains overwhelmingly favoured
by Dutch practitioners, NOACs are clearly gaining in pop-
ularity. Between 2011 and 2014, NOACs constituted an
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increasingly large proportion of prescriptions for oral anti-
coagulants.
The insights provided by the GARFIELD-AF registry
can be used by healthcare systems to inform better bud-
getary strategies, by practitioners to better tailor treatment
pathways to patients, and finally to promote awareness of
the various available treatment options and their associated
risks and benefits for patients.
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Introduction
Atrial fibrillation (AF) is the most commonly diagnosed
cardiac arrhythmia, with over 385,000 estimated cases [1]
in the Netherlands (5.5 % of the >55 year old age group).
With approximately 45,000 new cases [1] each year, AF
continues to grow at an alarming rate. Patients with AF have
a fivefold risk of suffering from ischaemic stroke [2, 3], and
are at considerably elevated risk for other thromboembolic
events [4, 5]. Moreover, strokes are twice as likely to be
lethal in patients with AF than in those without it [6]. The
need for good thrombotic prophylaxis is evident.
The most widely used method of reducing stroke and
other thromboembolic events in patients with AF is oral an-
ticoagulation. Oral anticoagulants are predominantly subdi-
vided into vitamin K antagonists (VKAs, e. g. warfarin) and
non-vitamin K antagonist oral anticoagulants (NOACs), the
latter subset comprising direct thrombin (dabigatran) and
factor Xa inhibitors (rivaroxaban, apixaban, edoxaban). In
the Netherlands, NOACs were only relatively recently ap-
proved: dabigatran in 2008, rivaroxaban in 2011, apixaban
in 2011 and edoxaban in 2015. Although clinical trials in-
Neth Heart J (2016) 24:574–580 575
dicate that NOACs are non-inferior, and in some respects
superior (e. g. fewer intracranial haemorrhages), to VKAs
[7], the number of patients treated with VKAs in the Nether-
lands still far exceeds the number of patients treated with
NOACs.
In the Netherlands, a system of anticoagulant clinics has
been in existence since the 1950s. This network of clinics
spans the country and monitors the vast majority of patients
on VKAs. Monitoring international normalised ratio (INR),
issuing recommendations on dose adjustment and registra-
tion of side effects and bleeding complications have been
routine practice for decades. When NOACs were intro-
duced, the Health Council of the Netherlands recommended
that these new agents should be carefully monitored, and
that their efficacy and complications should be registered
[8]. In spite of these recommendations, registration has not
yet been formalised in the form of study protocols, and at
present it remains uncertain whether proper monitoring of
the complications of NOACs will be institutionalised in the
same way it was for VKAs. This fact, combined with the
slow uptake of NOACs in the Netherlands so far, has pre-
cluded Netherlands-based observational research into their
relative risks and efficacy.
There are a number of reasons why it is important to
complement experimental data with real-life or observa-
tional, data. Firstly, study subjects and protocols in ex-
perimental (e. g. randomised controlled trial) settings have
often been found to inaccurately reflect the real patient pop-
ulation, i. e., key patient groups and typical care patterns
are underrepresented [9]. Secondly, observational studies
are able to incorporate a much wider range of potential risk
factors, allowing for analysis of more complex comorbidity
structures. Thirdly, and more pertinently for the prevention
of thrombosis in AF in particular, like many other countries,
the Netherlands could well be on the verge of a paradigm
shift from VKAs to NOACs as the predominant type of
thrombosis prophylaxis. Consequently, comparing adverse
event outcomes between these two types of anticoagula-
tion in a real-world setting will become increasingly more
important for the provision of good healthcare for patients
with AF.
Methods
The GARFIELD-AF registry was initiated to overcome the
dearth of information surrounding anticoagulation therapy,
by collecting and aggregating global data on treatment pat-
terns and clinical outcomes of non-valvular AF patients
with ≥1 additional risk factors for stroke into one obser-
vational dataset [10]. The particular utility of this registry
comes from its comprehensiveness, as: (1) the included
baseline characteristics cover a wide array of potential epi-
demiological risk factors; (2) the dataset comprises both
prospective and retrospective longitudinal cohorts; and (3)
as of June 2014, it included patient data (target n = 55,000,
current n = 41,677) from 35 different countries.
The data collected in the GARFIELD-AF registry will
be particularly salient to those researchers and practitioners
interested in: (1) the frequency of haemorrhagic and throm-
boembolic events in patients with AF, (2) INR fluctuations
for patients treated with VKAs, (3) therapy compliance and
persistence patterns [10]. Results relating to the above vari-
ables will be discussed in future GARFIELD-AF papers and
are not covered by this paper.
Patient inclusion criteria
All patients aged ≥18 years with a recent diagnosis
(6 weeks) of non-valvular AF who have at least one
additional risk factor for stroke and who have provided
written informed consent are eligible for inclusion in the
GARFIELD-AF registry. Patients to be included in the
retrospective cohort (see cohort enrolment) should have
been diagnosed within 6–24 months prior to enrolment into
the registry.
The follow-up duration D for all patients is 2 years 
D  8 years. Patients for whom further follow-up is not
expected or certifiably impossible are excluded from the
registry, as are patients whose transient AF is secondary to
a reversible cause.
Cohort enrolment
There is a total of six cohorts, the first of which is retrospec-
tive, and the rest of which are prospective and sequential.
All cohorts adhere to the same patient inclusion criteria, and
are methodologically different only in terms of the period
they cover. Patients included in the prospective cohorts (n =
50,000) are enrolled <6 weeks after diagnosis of AF, in five
sequential cohorts. Retrospective patients (n = 5000) are
enrolled 6–24 months after diagnosis. The results in this
paper were derived from the retrospective cohort and the
first three prospective cohorts, which span the periods De-
cember 2009 to October 2011, October 2011 to June 2013
and June 2013 to June 2014, respectively.
Data entry
All patient data are entered into a database by practition-
ers. In the Netherlands, these are general practitioners and
clinicians. Practitioners use the GARFIELD-AF electronic
case report form (eCRF) for data entry. The eCRF is an
online, multi-page questionnaire that addresses a host of
patient characteristics. Practitioners are instructed to enter
as much information about their patients as possible.
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Table 1 Baseline characteristics of GARFIELD-AF Dutch cohorts 1–3














Sex n (% male) 93 (66.7) 106 (67.9) 412 (55.1) 318 (58.2) 836 (57.9)
Age at diagnosis Mean (SD) 69.0 (9.3) 72.2 (8.7) 70.6 (10.2) 70.4 (9.9) 70.7 (9.9)
Type of AF diagnosed,
n (%)
Permanent 5 (5.4) 5 (4.7) 8 (1.9) 6 (1.9) 19 (2.3)
Persistent 10 (10.8) 7 (6.6) 32 (7.8) 7 (2.2) 46 (5.5)
Paroxysmal 22 (23.7) 15 (14.2) 82 (19.9) 36 (11.3) 133 (15.9)




VKA 66 (71.0) 74 (74.7) 285 (69.2) 218 (68.8) 577 (69.7)
VKA+AP 8 (8.6) 14 (14.1) 54 (13.1) 29 (9.1) 97 (11.7)
FXa – – 3 (0.7) 24 (7.6) 27 (3.3)
FXa+AP – – – 2 (0.6) 2 (0.2)
DTI 1 (1.1) – 6 (1.5) 16 (5.0) 22 (2.7)
DTI+AP – – 2 (0.5) 4 (1.3) 6 (0.7)
AP 11 (11.8) 6 (6.1) 32 (7.8) 10 (3.2) 48 (5.8)
None 7 (7.5) 5 (5.1) 30 (7.3) 14 (4.4) 49 (5.9)
Unknown – 7 – 1 8
Data from the first three GARFIELD-AF prospective cohorts – cohort 1: Dec 2009–Oct 2011; cohort 2: Oct 2011–Jun 2013; cohort 3: Jun
2013–Jun 2014
AP aspirin, FXa factor Xa inhibitor, DTI direct thrombin inhibitor
Non-compliance measures
The GARFIELD-AF eCRF incorporates a number of
entry options specifically relating to compliance and poten-
tial non-compliance indicators, e. g. dementia, low patient
motivation or poor access to INR monitoring (for VKAs),
as well as patient-indicated reasons for non-compliance,
e. g. a perception of low stroke risk versus high bleeding
risk, or certain dietary restrictions. This paper does not
cover non-compliance related results.
Results
As of June 2014, the Dutch sample included in GAR-
FIELD-AF comprised 929 patients in three cohorts.
Table 1 depicts a selection of descriptive statistics for
the Dutch GARFIELD-AF cohorts 1 through 3. Table 2
depicts a number of baseline factors that may contribute to
the occurrence of adverse events in patients with AF, such
as smoking status and CHA2DS2-VASc and HAS-BLED
scores.
The data show that the patients entering the sequential
cohorts are fairly consistent in age (Table 1) and CHA2DS2-
VASc score (Table 2), with an average age of 71 years
and risk score of 3 (SD 1.5). The majority of prospec-
tive patients were diagnosed with new-onset AF (73.6 %)
at baseline, followed by paroxysmal AF (15.9 %). A large
majority of prospective patients (81.4 %) were prescribed
VKA, or VKA combined with aspirin, at baseline (Table 1).
However, this proportion gradually diminished over time:
from 88.8 % in the period 2009–2011 to 77.9 % in the pe-
riod 2013–2014. This decrease occurred in unison with
the gradual uptake of NOACs (Fig. 1), which went from
0 % in 2009–2011 to 14.5 % (NOACs or a combination of
NOAC and aspirin at baseline) in 2013–2014 (Table 1).
At the same time, the proportion of patients not receiving
any form of antithrombotic medication is hardly affected,
varying between 4.4 and 7.3 % in this country (Fig. 1).
Worldwide, this group of subjects without antithrombotic
medication averages around 12 % and that proportion, too,
hardly changes in time (Fig. 1).
Discussion
The introduction of new medications to the anticoagulation
landscape has brought about changes in treatment patterns,
which may result in confusion with regard to effective anti-
coagulation management among patients and practitioners
without proper access to information. Now that the NOACs
have been shown to be effective and safe for use in clin-
ical trials, Phase IV research is needed to investigate the
real-world impact of these new drugs. The availability of
a large, variable-rich and non-interventional dataset such as
GARFIELD-AF may be used to advance our understanding
of how the various types of anticoagulation compare with
one another in their uptake and in daily management by pa-
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Table 2 Risk factors of GARFIELD-AF Dutch cohorts 1–3














Diabetes, n (%) Yes 20 (21.5) 20 (18.9) 81 (19.7) 58 (18.2) 159 (19.0)
Smoking status, n (%) No 26 (41.3) 31 (37.8) 134 (45.0) 127 (51.8) 292 (46.7)
Ex-smoker 26 (41.3) 37 (45.1) 119 (39.9) 75 (30.6) 231 (37.0)
Current smoker 11 (17.5) 14 (17.1) 45 (15.1) 43 (17.6) 102 (16.3)
Unknown 30 24 114 73 211
CHA2DS2-VASc score n (missing) 87 (6) 103 (3) 388 (24) 302 (16) 793 (43)
Mean (SD) 3.0 (1.3) 3.1 (1.5) 3.1 (1.5) 3.0 (1.5) 3.0 (1.5)
HAS-BLED score n (missing) 48 (45) 59 (47) 194 (218) 161 (157) 414 (422)
Mean (SD) 1.2 (0.9) 1.4 (1.0) 1.3 (0.9) 1.3 (0.9) 1.3 (0.9)
Data from the first three GARFIELD-AF prospective cohorts – cohort 1: Dec 2009–Oct 2011; cohort 2: Oct 2011–Jun 2013; cohort 3: Jun
2013–Jun 2014
tients, and which are consequently most suitable for real-
life scenarios.
The preliminary data, with a focus on the Netherlands in
this manuscript, show remarkable changes over time, with
substantial variation across countries. Within the Nether-
lands, a very gradual uptake of NOACs has been observed
compared with many other countries, including its neigh-
bour Belgium where only approximately 20 % of patients
with AF are still on VKA therapy (data not shown). This
rather striking contrast between the two countries may be
explained by the presence of a network of anticoagulation
clinics spanning the Netherlands; this situation is quite dif-
ferent in Belgium as well as many other countries around
the globe.
Among the consecutive cohorts, it should be noted that
a fairly fixed proportion of patients remain untreated; the
proportion of patients on aspirin appears to diminish in
time, which may in part be caused by a relatively larger
proportion of patients who receive an NOAC. Due to the
nature of this study we cannot, however, provide expla-
nations as to the decision-making processes that underlie
these apparent changes in prescriptions.
When compared with the pooled world data, it appears
that many patients in the Netherlands are prescribed oral
anticoagulants; usually they are prescribed VKA, in view
of the data presented in this paper. Obviously, VKA therapy
is challenging: it requires patient-specific titration and peri-
odic readjustment of the prescribed dose throughout therapy
to properly manage the patient’s prothrombin time, reflected
by the INR. VKA therapy is reasonably effective and safe
within an INR range of 2–3 (in the Netherlands, a slightly
higher range of 2.5–3.5 was preferred until recently) [11],
considering a time within therapeutic range (TTR) of >70 %
as optimal. According to the Rosendaal linear interpola-
tion technique, the average TTR (INR range 2.5–3.5) for
long-term users in the Netherlands is 81 % [12]. The fact
that VKA management requires frequent hospital visits and
blood sampling may also impact in different ways on the
inclination or ability of patients to initiate or continue ther-
apy [13]. Finally, VKAs have a host of food-drug and drug-
drug interactions [14], complicating their management still
further. In light of these issues, NOAC therapy offers many
practical advantages: NOACs are prescribed in fixed doses,
do not require continuous monitoring and have fewer inter-
actions with food and drugs. In spite of the potential ad-
vantages of NOACs there are still some hurdles, including
the persistent risk of major bleeding complications while on
oral anticoagulation [15]. NOACs remain under particular
scrutiny in this regard [16, 17], owing to the absence of ef-
fective antidotes to factor Xa and direct thrombin inhibitors
until recently [18]. However, this situation is changing;
a dabigatran antidote, idarucizumab, was approved by the
FDA at the end of last year and is currently registered in
the Netherlands too [19].
Perhaps the biggest impediment to treatment efficacy
is poor therapy compliance. Although non-compliance
patterns are diverse (e. g. regular short gaps in medication-
taking versus infrequent longer spells), the impact on treat-
ment efficacy often amounts to the same negative result.
This is particularly so for the NOACs, which have much
shorter half-lives than VKAs [2]. Research indicates that
suboptimal dabigatran adherence is associated with in-
creased risk for all-cause mortality and stroke [20]. This
underlines the pressing need to provide good information to
patients, but also to organise integrated antithrombotic care
for long-term users of anticoagulants. Integrated antithrom-
botic care has recently been recommended as standard care
in the nationally endorsed National Standard of Integrated
Antithrombotic Care 2.0 (LSKA 2.0) [21].
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Fig. 1 Treatment at diagnosis,
by cohort
The GARFIELD-AF registry has spawned several re-
search articles that attest to the usefulness of the dataset in
informing better anticoagulation practices. An analysis of
the characteristics of the first cohort (n = 10,614, spanning
19 countries, enrolment period December 2009 to October
2011) indicates that at the end of the VKA-only era, anti-
coagulant therapy was underused in patients at high risk of
stroke and overused in those at low risk [22]. Another, more
recent analysis confirmed these findings and also showed
that more women than men were at moderate-to-high risk
of stroke [23]. GARFIELD-AF is among the largest and
longest-running of several recent large-scale observational
registries charting anticoagulation use and outcomes in AF.
National initiatives, such as the PINNACLE (Practice
INNovation And Clinical Excellence), ORBIT-AF (Out-
comes Registry for Better Treatment of Atrial Fibrillation),
the Paul Coverdell National Acute Stroke Registry, AFNET
(the German Competence Network on Atrial Fibrillation)
and regional initiatives, such as PREFER in AF (Prevention
of thromboembolic events – European Registry in Atrial
Fibrillation) supplement more broad-scoped registries with
a localised focus, including RealiseAF (Real-life global sur-
vey evaluating patients with atrial fibrillation), RecordAF
(REgistry on Cardiac rhythm disORDers assessing the con-
trol of Atrial Fibrillation) and GLORIA-AF (Global Reg-
istry on Long-Term Oral Antithrombotic Treatment in Pa-
tients with Atrial Fibrillation).
Large registries such as those described above present
a number of real benefits to the various groups in society in-
volved in antithrombotic therapy of AF patients. Healthcare
systems will be able to better analyse budgetary impacts in
the continuously evolving anticoagulation landscape; clin-
icians are aided in customising therapy trajectories to best
benefit their patients, based on the myriad factors that con-
tribute to interindividual variability (e. g. non-compliance
risk factors, comorbidity profiles, renal function); the data
could also be used to promote patient understanding of the
various competing treatment options and their associated
risks and benefits. In the Netherlands, where such aware-
ness is still not optimal, the impact of the GARFIELD-AF
registry and others of its ilk could be beneficial.
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